Source link : https://www.newshealth.biz/health-news/covid-preventive-drug-should-work-against-circulating-variants-fda-now-says/
The FDA has determined that the monoclonal antibody pemivibart (Pemgarda) is likely to be effective against currently circulating SARS-CoV-2 variants, including KP.3.1.1 and LB.1. “Based on current CDC Nowcast estimates and variant spike receptor binding domain similarity to tested variants, FDA anticipates Pemgarda will retain activity against the currently circulating variants in the U.S.,” the […]
Author : News Health
Publish date : 2024-09-27 15:43:10
Copyright for syndicated content belongs to the linked Source.